Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Pacira Pharmaceuticals ( (PCRX) ) is now available.
On July 9, 2025, Pacira BioSciences, Inc. implemented a workforce reduction at its San Diego Science Center Campus due to improved manufacturing efficiencies for EXPAREL, resulting from investments in large-scale manufacturing suites. This decision led to the decommissioning of a 45-liter manufacturing suite and affected 71 employees, approximately 8% of the workforce. The company anticipates recognizing pre-tax charges of $2.4 million to $2.8 million related to employee termination benefits and expects an annual reduction in operating expenses of approximately $13 million. The move reflects Pacira’s strategic focus on optimizing production capacity and cost structure to support growing demand for its products.
The most recent analyst rating on (PCRX) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Pacira Pharmaceuticals stock, see the PCRX Stock Forecast page.
Spark’s Take on PCRX Stock
According to Spark, TipRanks’ AI Analyst, PCRX is a Neutral.
The overall score is primarily impacted by strong earnings call sentiment and strategic initiatives, offset by poor technical analysis and valuation metrics. Financial performance is stable, but high leverage and profitability challenges remain.
To see Spark’s full report on PCRX stock, click here.
More about Pacira Pharmaceuticals
Pacira BioSciences, Inc. operates in the pharmaceutical industry, focusing on non-opioid pain management solutions. Its primary products include EXPAREL, a bupivacaine liposome injectable suspension, ZILRETTA, and iovera°. The company is committed to advancing non-opioid pain management and has invested in large-scale manufacturing to meet growing demand.
Average Trading Volume: 704,458
Technical Sentiment Signal: Sell
Current Market Cap: $1.07B
For a thorough assessment of PCRX stock, go to TipRanks’ Stock Analysis page.